<DOC>
	<DOCNO>NCT00398385</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know whether give chemotherapy surgery effective give surgery treat non-small cell lung cancer . PURPOSE : This randomized phase II trial study gemcitabine cisplatin compare well work give surgery treat patient stage I stage II non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Cisplatin Before After Surgery Treating Patients With Stage I Stage II Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time recurrence patient stage IB II non-small cell lung cancer treat neoadjuvant versus adjuvant gemcitabine hydrochloride cisplatin . Secondary - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient . - Compare complete resection rate without neoadjuvant gemcitabine hydrochloride cisplatin . OUTLINE : This randomize study . Patients stratify disease stage ( IB v II ) histology ( squamous cell carcinoma vs nonsquamous cell carcinoma ) . Patients randomize 1 2 treatment arm . - Arm I ( neoadjuvant chemotherapy ) : Patients receive gemcitabine hydrochloride IV 30 minute cisplatin IV 30 minute day 1 15 . Treatment repeat every 4 week 4 course absence disease recurrence unacceptable toxicity . Within 8 week initiate course 4 chemotherapy , patient undergo complete surgical resection . - Arm II ( adjuvant chemotherapy ) : Patients undergo complete surgical resection . Beginning within 8 week complete surgical resection , patient receive gemcitabine hydrochloride IV cisplatin IV arm I . Quality life assess baseline periodically 5 year . After completion study therapy , patient follow periodically least 5 year disease recurrence . PROJECTED ACCRUAL : A total 170 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Squamous cell nonsquamous cell histology Stage IB II disease Tumor amenable curative surgical resection PATIENT CHARACTERISTICS : ECOG performance status 01 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study therapy Medical fitness must adequate radical NSCLC surgery WBC ≥ 4,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin normal ALT AST ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL No second primary malignancy No active uncontrolled infection No concurrent serious disorder would compromise patient safety tolerance study therapy No significant neurological mental disorder No myocardial infarction within past 6 month No symptomatic heart disease , include follow : Unstable angina Congestive heart failure Uncontrolled arrhythmia PRIOR CONCURRENT THERAPY : No prior chemotherapy anticancer therapy No prior surgery NSCLC No prior concurrent radiotherapy immunotherapy ( e.g. , biologic response modifier ) No major surgery ( biopsy ) within past 2 week No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IB non-small cell lung cancer</keyword>
	<keyword>stage IIA non-small cell lung cancer</keyword>
	<keyword>stage IIB non-small cell lung cancer</keyword>
</DOC>